ImCyse Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 45
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $25.9M
Latest Deal Amount
  • Investors
  • 10

ImCyse General Information

Description

Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines help to destroy locally the immune cells involved in the destruction of the diseased organ for the generation of a new type of T-cell called cytolytic CD4 and prevent the immunogenic responses that weaken the efficiency of chronic therapies, enabling physicians to treat and prevent severe chronic diseases caused by disruptions of the immune system.

Contact Information

Website
www.imcyse.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • GIGA B34
  • Avenue Pré-Aily 14
  • 4031 Liege
  • Belgium
+32 04 000 00 00

ImCyse Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ImCyse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 03-Feb-2021 $25.9M 000.00 00000 Completed Clinical Trials - Phase 2
7. Grant 18-Jun-2019 00.000 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 18-Jun-2019 000.00 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC 30-Nov-2017 00.000 00.000 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC 27-Aug-2014 00.000 00.000 000.00 Completed Startup
3. Later Stage VC 01-Nov-2012 00.000 00.000 000.00 Completed Startup
2. Later Stage VC 09-Feb-2011 $270K $270K 00000 Completed Startup
1. Accelerator/Incubator 01-Jan-2011 Completed Startup
To view ImCyse’s complete valuation and funding history, request access »

ImCyse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B 000,000 00.000000 000.0 000.0 00 000.0 00.000
Class E 00,000 000.00 000.00 00 000.00 0.000
Class C 000 000.00 000.00 00 000.00 0.000
Class B 000 000.00 000.00 00 000.00 0.000
Class D 00,000 00.00 00.00 00 00.00 0.000
Class C 0,000 00.00 00.00 00 00.00 0.000
Class E 000,000 000.00 000.00 00 000.00 00.000
Class B 0,000 000.00 000.00 00 000.00 0.000
Class E 39,168 $24.9 $24.9 1x $24.9 1.34%
Class C 469 $24.9 $24.9 1x $24.9 0.02%
To view ImCyse’s complete cap table history, request access »

ImCyse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines
Drug Discovery
Liege, Belgium
45 As of 2021
000.00
0000 0000-00-00
00000000000 000.00

00000

a. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Cambridge, United Kingdom
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

00000000

a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea c
0000 000000000
Cambridge, United Kingdom
00 As of 0000
00000
000 0000-00-00
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImCyse Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
000000000 00000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 0000000000 0 00000
You’re viewing 2 of 2 competitors. Get the full list »

ImCyse Patents

ImCyse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019379760-A1 Immunogenic peptides with new oxidoreductase motifs Pending 12-Nov-2018 00000000000
CA-3118620-A1 Immunogenic peptides with new oxidoreductase motifs Pending 12-Nov-2018 00000000000
AU-2019377983-A1 Immunogenic peptides with improved oxidoreductase motifs Pending 12-Nov-2018 00000000000
EP-3880237-A2 Immunogenic peptides with improved oxidoreductase motifs Pending 12-Nov-2018 00000000000
EP-3880236-A2 Immunogenic peptides with new oxidoreductase motifs Pending 12-Nov-2018 A61K39/0008
To view ImCyse’s complete patent history, request access »

ImCyse Executive Team (13)

Name Title Board Seat Contact Info
Denis Bedoret Chief Executive Officer
Antoon Oosterhout Ph.D Chief Scientific Officer & Vice President, Research & Development
Luc Elst Ph.D Co-Founder & Director, Research & Development
Vincent Carlier Ph.D Co-Founder & Research & Development Director, Immunology
Jean Smal Senior Advisor, Development and Manufacturing
You’re viewing 5 of 13 executive team members. Get the full list »

ImCyse Board Members (11)

Name Representing Role Since
Christina Franssen Ph.D Société Régionale d'Investissement de Wallonie Board Member 000 0000
Hugues Wallemacq Ph.D Noshaq Board Member 000 0000
Jean Foidart ImCyse Chairman of Scientific Advisory Board 000 0000
Stefan Yee Self Board Member 000 0000
Stijn Van Rompay Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

ImCyse Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImCyse Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Pfizer Corporation Minority 000 0000 000000 0
Biogenosis Corporation Minority 000 0000 000000 0
Epimède Venture Capital Minority 000 0000 000000 0
Federal Holding and Investment Company Holding Company Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »